



Contents lists available at ScienceDirect

Chemical Engineering Journal

journal homepage: www.elsevier.com/locate/cej

Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems

Dana da Silva^a, Maya Kaduri^a, Maria Poley^a, Omer Adir^{a,b}, Nitzan Krinsky^{a,c}, Janna Shainsky-Roitman^a, Avi Schroeder^{a,*}

^a Laboratory for Targeted Drug Delivery and Personalized Medicine Technologies, Department of Chemical Engineering, Technion – Israel Institute of Technology, Haifa 32000, Israel

^b The Norman Seiden Multidisciplinary Program for Nanoscience and Nanotechnology, Technion – Israel Institute of Technology, Haifa 32000, Israel

^c The Interdisciplinary Program for Biotechnology, Technion – Israel Institute of Technology, Haifa 32000, Israel

HIGHLIGHTS

- Polylactic acid (PLA) is a biocompatible polymer that is used widely for biomedical applications.
- PLA biodegrades into lactic acid (LA) or to carbon dioxide and water.
- PLA degradation products are metabolized intracellularly or excreted in the urine and breath.
- Adverse reactions or foreign body response to PLA are extremely rare.

ARTICLE INFO

Keywords:

Poly(lactic) acid
Polymer
Safety
Biodegradation
Elimination
Excretion
Poly(lactic) acid
Drug delivery
Tissue engineering
Drug targeting

ABSTRACT

Poly(lactic) acid (PLA) is the most commonly used biodegradable polymer in clinical applications today. Examples range from drug delivery systems, tissue engineering, temporary and long-term implantable devices; constantly expanding to new fields. This is owed greatly to the polymer's favorable biocompatibility and to its safe degradation products. Once coming in contact with biological media, the polymer begins breaking down, usually by hydrolysis, into lactic acid (LA) or to carbon dioxide and water. These products are metabolized intracellularly or excreted in the urine and breath. Bacterial infection and foreign-body inflammation enhance the breakdown of PLA, through the secretion of enzymes that degrade the polymeric matrix.

The biodegradation occurs both on the surface of the polymeric device and inside the polymer body, by diffusion of water between the polymer chains.

The median half-life of the polymer is 30 weeks; however, this can be lengthened or shortened to address the clinical needs. Degradation kinetics can be tuned by determining the molecular composition and the physical architecture of the device. For example, using L- or D-chirality of the LA will greatly lengthen or shorten the degradation rates, respectively.

Despite the fact that this polymer is more than 150 years old, PLA remains a fertile platform for biomedical innovation and fundamental understanding of how artificial polymers can safely coexist with biological systems.

1. Introduction

Polymers are probably the most important and widely used class of materials that contributed to the industrial revolution. The ability to tailor a polymer's mechanical properties and bio-degradation kinetics, made these materials extremely appealing for biomedical applications [1–7].

Lactic acid (LA) is a naturally-occurring compound, which is the precursor of downstream metabolic product of pyruvate, through the

Cori cycle [8,9]. LA can also be manufactured synthetically in large scale by the fermentation of corn, beets and carbohydrates from other crops [10]. The monomeric form of LA is approved by the regulatory agencies as a food additive [11].

Poly(lactic) acid (PLA), was first synthesized by the French chemist Theophile-Jules Pelouze in 1845, through the poly-condensation of LA into low molecular weight PLA, ranging from 800 to 5000 g/mol [12]. Later, DuPont's chemist Wallace Hume Carothers, inventor of nylon, improved the production process, enabling to increase the average

* Corresponding author.

E-mail address: avids@technion.ac.il (A. Schroeder).

<https://doi.org/10.1016/j.cej.2018.01.010>

1385-8947/ © 2018 Elsevier B.V. All rights reserved.




Fig. 1. Natural biodegrading pathways of poly(lactic acid) (PLA) in primary sites of medical device implantation. The main mechanism for PLA degradation inside the body is hydrolysis of the ester-bond backbone. The degradation rate is dependent on pH and temperature in the tissue, on the one hand, and on the composition of the polymer, on the other. Therefore the degradation rate in sites of inflammation will be higher compared to healthy tissues. Chirality also affects the degradation rate; D-PLA will degrade faster compared to L-PLA. This enables to tailor the implant to the desired organ and for the desired biomedical application.

molecular weight of the polymer to 100,000 g/mol [13]. This improved PLA's mechanical properties, making it a promising new candidate to compete with other commercial polymers. However, PLA's costly production process hampered broad implementation, narrowing the polymer's use to biomedical applications. In 1989, Dr. Patrick R. Gruber invented a low-cost commercial process for producing high molecular weight PLA, expanding its use to many additional areas, such as agricultural sheets and biodegradable disposable bags [14]. In fact, today PLA is the second most traded polymer worldwide [15].

The surge in the biomedical use of PLA is evident even after a brief look at the increasing number of publications in the field, averaging above 1000 research papers per year over the past five years (PubMed; search term: polylactic acid). The impact of PLA is increasingly growing as new modes for tailoring the polymer's properties to address different biomedical needs are being discovered (Fig. 1). It is estimated that the biomedical market of PLA is expanding by more than 10% annually, making it one of the most important polymers in biomedical use [16].

This review focuses on the biocompatibility of PLA with special attention to the biodegradation and bio-elimination this class of polymers has inside the body.

2. Permanent and temporary biomedical systems

Biomedical systems can be divided into two groups: permanent and temporary [17–20]. For example, we would want an artificial knee to

be non-degradable and permanent, so that the patient would not need to undergo replacement surgeries every decade [21]. Contrarily, sutures should ultimately degrade after the sewed tissue heals and regains sufficient physical strength to support itself [22–24]. In another example, in the past, when orthopedic surgeons used screws during repair processes these were permanent, displacing any bone that could have grown back over time [1,25–29]. New materials, such as PLA, have transient properties, starting strong and supportive, and degrading over time to give space to newly grown bone to take over the space the device took in the body [30]. Table 1 summarizes different PLA-based devices and their degradation profiles.

3. PLA chemistry

Lactide, PLA's primary monomeric building block, can have L-lactide or D-lactide chirality. Selecting L-chirality over D will determine the polymer's biodegradability and mechanical properties, as well as if the polymer is semi-crystalline or amorphous, respectively. In general, the D and L/D forms degrade more rapidly than the L form [40–42].

PLA, having L, D or L/D (the former, a blend of both enantiomers) forms, is semi-permeable to water and oxygen, making it even more susceptible to biodegradation compared to other biomedical polymers [16,43]. Increasing the porosity of the polymer, or the surface area-to-volume ratio, will enhance the degradation rate [44]. Moreover, when the device is porous, the degradation will occur both on the outer

Table 1
PLA-based formulations degradation profiles.

PLA composition	Chirality	Degradation conditions	Degradation time	Usage	References
(PEG-5 k)2-tartarate-PLA	D,L	<i>In vitro</i> : 0.1 M phosphate buffer, pH 7.4, 37 °C	60% weight loss after 4 weeks	Drug delivery nanospheres	[3]
PLA-octreotide microparticles	D	<i>In vitro</i> : 0.1 M phosphate buffer, pH 7.4, 37 °C	15–30% weight loss after 40 days	Octreotide drug delivery	[4]
PLA-octreotide microparticles	D,L	<i>In vitro</i> : 0.1 M phosphate buffer, pH 7.4, 37 °C	10–20% weight loss after 40 days	Octreotide drug delivery	[4]
PLA fibers	–*	<i>In vivo</i> : rat oral tissue	Full degradation between 42 and 70 days	Sutures	[23]
PLA	D,L	<i>In vitro</i> : 0.13 M phosphate buffer, pH 7.4, 37 °C	Plates: 11 weeks Films: 25 weeks	Size-dependence degradation testing	[31]
PLA films-initial Intrinsic viscosity OF 3.24 dL/g	D,L	<i>In vivo</i> : subdermal implantation in rabbits	58% weight loss over 60 weeks	Experimental degradation rate study	[32]
PLA films	L	<i>In vitro</i> : 0.2 M citrate buffer, pH 7, 37 °C	10% weight loss over 16 weeks	Materials in surgery	[33]
PLA microcapsules	D,L	<i>In vivo</i> : Intra-muscular injection to rats	Breakdown first observed after 150 days and total erosion after 420 days	Drug delivery	[34]
PLA microspheres	L	<i>In vivo</i> : injection to rats' livers	Implant conserved its geometrical form 14 months after injection	Drug delivery	[35]
PLA implant	L	<i>In vivo</i> transplantation to rats	14% weight loss after 3 months	Implants	[36]
PLA sheet	–*	<i>In vivo</i> : transplantation in the infraorbital rim of macace monkeys	Remnants found at the surgical site 38-weeks post implantation	PLA bone implants	[37]
PLA-Zn 0.05% (98% L)	D,L	<i>In vitro</i> : 0.13 M phosphate buffer, pH 7.4, 37 °C	9% weight loss after 12 months	PLA screws	[38]
PLA plates	D,L	<i>In vivo</i> : subperiosteal in rabbits	70% loss of molecular weight after 42 days	PLA bone implants	[39]

* Chirality isn't indicated.

surface and in the inner core of the polymer [45].

4. The biodegradation of PLA

ASTM International Standardization Organization (standard #D-5488-94d) defines 'biodegradable' as 'capable of undergoing decomposition into carbon dioxide, methane, water, inorganic compounds, and biomass' [16].

The primary mechanism by which PLA is degraded inside the body is hydrolysis of the ester-bond backbone, Fig. 2 [31]. The degradation products can be either monomeric LA or oligomers of LA. The hydrolytic degradation is then further catalyzed by the newly-formed carboxylic groups at the terminal ends of the cleaved PLA chains [32].

Degradation occurs on the surface of the polymer and inside the polymer bulk, creating LA monomers and oligomers [46]. Moreover, the diffusion of water into the polymer bulk degrades the polymer microstructure through the formation of internal cavities [46]. The cleaved monomers will diffuse out of the polymer over time; however, the diffusion of hydrolyzing water molecules throughout the polymer is far more rapid.

The degradation of PLA is greatly dependent on pH and temperature [33,47]. Xu and co-workers [47] demonstrated that in physiological pH of 7.4 PLA brushes have a degradation time of 100 h, while in acidic pH of 3 there was no apparent degradation after 400 h. They also showed that PLA's degradation rate was 4-folds faster in 37 °C in comparison to

25 °C in which full degradation occurred after 400 h. Increasing the temperature further to 60 °C resulted in an even faster degradation, reaching full degradation after less than 10 h. The effect of pH on the degradation time can be utilized in order to tailor the half-life of the polymer construct towards the target tissue, as different tissues have different pH ranges [48,49].

Kulkarni and co-workers [50] measured the degradation kinetics of PLA in biological media. They found that the polymer degrades by random scission of the polymer backbone, obeying second-order kinetics, having an activation energy of 11 kcal/mol. Interestingly, they and others show that L-PLA degrades in a slower manner compared to the D/L-PLA.

Beck and coworkers showed that the half-life of D/L-PLA microspheres injected intramuscularly to rats was 34 weeks [35,51,52]. Incorporating other monomers into the PLA matrix, increased the degradation rate; reiterating the concept that neat PLA polymer has slower degradation compared to di-block polymers.

In another study, Reed and Gilding [33], demonstrated that PLA sutures lose 50% of their weight after approximately 14 weeks at pH 7 and 37 °C. However, the weakening in the suture's tensile strength is far more rapid, declining 50% over 6–8 weeks. This indicates that the degradation process is not only erosion of the suture's surface, but also internal cleavage of molecular bonds inside the suture bulk, without mass loss [31,53].

Multi-year degradation rates may be less suitable for drug delivery systems. To increase the degradation rate, PLA foams were created [45]. These systems have an extremely high surface area/polymer weight ratio, as well as large internal volumes into which the drugs are loaded. Such systems can release therapeutic doses of the drugs immediately after implantation and over several months [9,54–58].

5. Enzymatic biodegradation

In 1981 David Franklin Williams discovered the ability to enzymatically degrade PLA into LA [59]. Surprisingly, he showed that proteinase K (sourced from *Tritirachium album*) and pronase (sourced from *Streptomyces griseus*) detached the PLA polymeric matrix at 37 °C. Later, it was shown that PLA-depolymerase, a 24 kDa bacterial enzyme, degrades PLA into monomeric LA [60,61]. While such enzymes may be associated with infection, also inflammation can catalyze the




Fig. 2. The chemical synthesis and natural biodegradation pathway of poly(lactide) (PLA) *in vivo*. The synthesis of PLA is initiated by poly-condensation of lactic acid into low molecular weight polymer. Biodegradation occurs mostly at the inflammation site and enhanced by acid phosphatase and lactate dehydrogenase secreted by fibroblasts, macrophages and neutrophils.

degradation of PLA. Specifically, when any polymeric object is implanted in the body, a foreign body immune response is triggered [36,62]. Immune cells swarm to the site of implantation to detect, quarantine and remove the foreign object [63]. These cells, include neutrophils, macrophages and fibroblasts, secrete an array of enzymes, such as acid phosphatase and lactate dehydrogenase, which enhance PLA degradation [57,64,65].

6. Clinical degradation and excretion of PLA

Stener and coworkers examined 77 patients eight years after being implanted L-PLA screws in their tibia and femur during tendon reconstruction [66]. The recovery of the PLA-treated group was similar to patients implanted with metal screws. One advantage a biodegradable screw grants is the ability to be replaced by endogenous tissue, during the healing and reconstruction process [2]. The half-life of L-PLA screws in tissue averages 24 months, versus, 12 months of L/D-PLA screws [2].

Facial reconstruction surgeries after trauma also demonstrated excellent tissue compatibility [37]. Remnants of the PLA implants (sheets) were found at the surgical site 38-weeks post implantation.

Upon tissue implantation, the PLA polymer is coated by phagocytic cells and a fibrous capsule, denoting a foreign body reaction [36]. A close look at radiolabeled PLA degradation products indicated these are secreted from the body, and not retained in any primary organ [36]. It is assumed excretion occurs through kidney filtration and urine or as carbon dioxide.

Cutright and Hunsuck [23], noticed that the diameter of PLA sutures increased slightly after implantation. This is most likely due to the diffusion of water between the polymer chains. They noticed the suture is partially degraded one month post implantation, but remnants of the suture were found in the tissue nearly two months after the procedure [23].

7. Polylactic acid in theranostics

The favorable biocompatibility of PLA has been utilized for combined drug delivery systems and diagnostics [22,67]. For example, polymeric micelles (mean size of 20 nm) accumulated in glioma tumors in mice 24 h after intravenous administration [68]. To improve tissue-specific targeting various ligands (such as antibodies and sugars) are conjugated to the corona of the particles [69]. Liu and co-workers loaded PLA-based nanoscale micelles with the anti-cancer agent paclitaxel, together with the MRI contrast agent Gadolinium (Gd) and a specific cancer marker antibody [70]. In this manner they were able to track the biodistribution and targeting capacity of the nanoparticles to H22 (liver cancer) tumors, as well as observe the therapeutic response to the treatment. In a similar manner, Yang *et al.* developed PLA-based nanoparticles for siRNA co-delivery together with fluorescent and MRI diagnostic contrast agents [71]. These studies emphasize the modularity of PLA; allowing block polymerization with other materials such as polyethylene glycol (PEG), or complexation with inorganic materials such as iron-oxide and gold nanoparticles [72]. The ability to engineer modular theranostic systems of nanoscale dimensions which are safely biodegraded and secreted, opened the door to new applications that combine therapy and diagnostics [67,73–77].

8. Adverse reactions

In the enormous body of literature, and thousands of clinical reports regarding the use of PLA devices since the 1980's, we found only several reports that describe adverse effects of PLA in patients.

L-PLA orthopedic implant' complications may occur due to physical damage of the instrument or migration within joints [78]. For example, a posterior cruciate ligament reconstruction performed on a 16-year-old patient resulted in synovitis due to breakage of an L-PLA screw 2 years post implantation, required the removal of the screw fragments. In

another case, 15 months after an anterior cruciate ligament reconstruction, the patient suffered from pain and swelling after the biodegradable screw broke and its head migrated intra-articularly. Awareness to the possible screw breakage and performing arthroscopy, if symptoms arise, can enable immediate removal of the damaged implant and minimizing further adverse effects [25]. However, these examples are rare, and in general only 0.2% of the procedures involved PLA implants present a foreign body reaction [79], as a result from the new interaction of the tissue and device at the implementation site and the device breakdown. It includes protein absorption, recruitment of macrophages and foreign body giant cells [80,81]. A foreign body reaction is manifested as a cyst-like mass and can be addressed by the removal of device fragments [81,82].

In one report, a systemic allergic reaction occurred in a 30-year-old patient, after being implanted with PLA screws for anterior cruciate ligament reconstruction [83]. The patient suffered from a rash in the right femur, chronic fatigue, and localized alopecia. A skin end-point titration revealed that the PLA screws had allergenicity in this patient, by evaluating the skin reaction towards different concentration of PLA antigen solution [84]. After total removal of the screws, the symptoms disappeared. When PLA was injected intra-dermally, mild nodularity at the site of the injection were reported [85]. When an improper injection technique (incorrect depth for example) was applied, intraoral lesions were observed due to the migration of the dermal filler substance [86]. In summary, few patients were reported to have allergic responses to PLA. However, breakage, or wearing-down of the medical implant can induce foreign body reaction and inflammation. Tuning the mechanical properties of the polymer to the application site, is a prerequisite for a successful implant.

9. PLA in three dimensional (3D) printing technologies

Polymeric based 3D scaffolds have become a fundamental part of tissue engineering [87]. They are used *in vitro* as a platform for cell adhesion that simulates the ECM mechanical support, and *in vivo* as templates for organ regeneration. Table 2 summarizes different PLA based scaffolds printed with a 3D system. Scaffold design has a great impact on scaffolds' mechanical properties and permeability. PLA high quality and resolution 3D scaffolds can be fabricated using 3D printing techniques [88]. For example, patient-specific scaffold design can be produced according to the anatomical data of the specific patient [89]. PLA is one of the most common biodegradable polymers used for 3D scaffold printing. The biodegradation time of PLA makes it a very attractive candidate for *in vivo* implantation. Recently, different combinations of PLA with other materials such as glass particles and PEG have been used to better control the scaffolds physical and mechanical properties and to improve the printing process [90–92].

10. Summary

Polylactic acid is widely used clinically as a biomedical scaffold for

Table 2
PLA-based scaffolds printed with a 3D system.

Material	Experiment	Application	References
PLA/Polydopamine	<i>In vitro</i> – hADSCs	Craniomaxillofacial bone lesion repair	[93]
PLLA/PLGA	<i>In vitro</i> – Human skin fibroblasts	Tissue engineering – skin fibroblasts	[94]
HA/Collagen/PLA	<i>In vivo</i> – Rabbits	Bone scaffold	[95]
PLA/PEG/G5 glass particles	<i>In vitro</i> – rMSC adhesion	Tissue engineering	[96]
PLA/ β -TCP	<i>In vivo</i> – Rabbits	Heterotopic bone formation	[97]
PDLA/rhBMP-2	<i>In vivo</i> – Rats	Mandibular bone repair	[98]

implants, theranostics and drug delivery systems. It is simple to synthesize, and can be tailored for different therapeutic needs. PLA is naturally degraded over time into well-tolerated and safe degradation products, which are secreted from the body. When coming to design new systems with biomedical applications, considering PLA as a scaffold may prove as a wise decision.

Acknowledgements

This work was supported by ERC-STG-2015-680242. The authors also acknowledge the support of the Technion Integrated Cancer Center (TICC), the Russell Berrie Nanotechnology Institute, the Lorry I. Lokey Interdisciplinary Center for Life Sciences & Engineering, the Pre-Clinical Research Authority staff and the Biomedical Core Facility at the Rappaport Faculty of Medicine, as well as the Israel Ministry of Economy for a Kamin Grant (52752); the Israel Ministry of Science Technology and Space – Office of the Chief Scientist (3-11878); the Israel Science Foundation (1778/13); the Israel Cancer Association (2015-0116); the German-Israeli Foundation for Scientific Research and Development for a GIF Young grant (I-2328-1139.10/2012); the European Union FP-7 IRG Program for a Career Integration Grant (908049); a Mallat Family Foundation Grant; A.S. acknowledges Alon and Taub Fellowships. Ms. Krinsky wishes to thank the Baroness Ariane de Rothschild Women Doctoral Program for its generous support. Omer Adir acknowledges the support of the Technion Interdepartmental Nanotechnology Program.

References

- J.C. Middleton, A.J. Tipton, Synthetic biodegradable polymers as orthopedic devices, *Biomaterials* 21 (2000) 2335–2346.
- S.Y. Zhang, A.M. Bellinger, D.L. Glettig, R. Barman, Y.A.L. Lee, J.H. Zhu, C. Cleveland, V.A. Montgomery, L. Gu, L.D. Nash, D.J. Maitland, R. Langer, G. Traverso, A pH-responsive supramolecular polymer gel as an enteric elastomer for use in gastric devices, *Nat. Mater.* 14 (2015) 1065.
- S. Ben-Shabat, N. Kumar, A.J. Domb, PEG-PLA block copolymer as potential drug carrier: preparation and characterization, *Macromol. Biosci.* 6 (2006) 1019–1025.
- A. Bishara, A.J. Domb, PLA stereocomplexes for controlled release of somatostatin analogue, *J. Control. Release* 107 (2005) 474–483.
- J. Slager, A.J. Domb, Heterostereocomplexes prepared from D-PLA and L-PLA and leuprolide. II. Release of leuprolide, *Biomacromolecules* 4 (2003) 1316–1320.
- M. Manzano, M. Vallet-Regí, New developments in ordered mesoporous materials for drug delivery, *J. Mater. Chem.* 20 (2010) 5593–5604.
- M. Kar, M. Molina, M. Calderon, How are we applying nanogel composites in biomedicine? *Nanomedicine (Lond)* 12 (2017) 1627–1630.
- L. Pasteur, Mémoire sur la fermentation appelée lactique, *Compt. Rendus Chim.* 45 (1857) 913–916.
- S. Cohen, T. Yoshioka, M. Lucarelli, L.H. Hwang, R. Langer, Controlled delivery systems for proteins based on poly(lactic/glycolic acid) microspheres, *Pharm. Res.* 8 (1991) 713–720.
- R.A. Auras, L.-T. Lim, S.E.M. Selke, H. Tsuji, *Poly(lactic acid): Synthesis, Structures, Properties, Processing, and Applications*, John Wiley & Sons, 2011.
- F.S. Agency, Current EU Approved Additives and Their E Numbers, in, 2014.
- L.T. Lim, R. Auras, M. Rubino, Processing technologies for poly(lactic acid), *Prog. Polym. Sci.* 33 (2008) 820–852.
- W.H. Carothers, J.W. Hill, Studies of polymerization and ring formation. XII. linear superpolyesters, *J. Am. Chem. Soc.* 54 (1932) 1559–1566.
- R.E. Drumright, P.R. Gruber, D.E. Henton, Polylactic acid technology, *Adv. Mater.* 12 (2000) 1841–1846.
- Lactic Acid Market Analysis By Application (Industrial, F&B, Pharmaceuticals, Personal Care) & Poly(lactic acid) (PLA) Market Analysis By Application (Packaging, Agriculture, Transport, Electronics, Textiles), And Segment Forecasts, 2014–2025, in, Grand View Research, 2017.
- L. Avérous, E. Pollet, *Biodegradable polymers, Environmental Silicate Nano-Biocomposites*, Springer-Verlag, London, 2012.
- A.R. Amini, J.S. Wallace, S.P. Nukavarapu, Short-term and long-term effects of orthopedic biodegradable implants, *J. Long Term Eff. Med. Implants* 21 (2011) 93–122.
- E. Miceli, M. Kar, M. Calderón, Interactions of organic nanoparticles with proteins in physiological conditions, *J. Mater. Chem. B* 5 (2017) 4393–4440.
- E. Fleige, M.A. Quadir, R. Haag, Stimuli-responsive polymeric nanocarriers for the controlled transport of active compounds: concepts and applications, *Adv. Drug Deliv. Rev.* 64 (2012) 866–884.
- J. Khandare, M. Calderon, N.M. Dagia, R. Haag, Multifunctional dendritic polymers in nanomedicine: opportunities and challenges, *Chem. Soc. Rev.* 41 (2012) 2824–2848.
- P.C. Kreuz, S. Muller, C. Ossendorf, C. Kaps, C. Ergelet, Treatment of focal degenerative cartilage defects with polymer-based autologous chondrocyte grafts: four-year clinical results, *Arthritis Res. Ther.* 11 (2009) R33.
- G.L. Racey, W.R. Wallace, C.J. Cavalari, J.V. Marguard, Comparison of a polyglycolic-poly(lactic acid) suture to black silk and plain catgut in human oral tissues, *J. Oral Surg.* 36 (1978) 766–770.
- D.E. Cutright, E.E. Hunsuck, Tissue reaction to the biodegradable polylactic acid suture, *Oral Surg. Oral Med. Oral Pathol.* 31 (1971) 134–139.
- C.B. Weldon, J.H. Tsui, S.A. Shankarappa, V.T. Nguyen, M. Ma, D.G. Anderson, D.S. Kohane, Electrospun drug-eluting sutures for local anesthesia, *J. Control. Release* 161 (2012) 903–909.
- B.L. Shafer, P.T. Simonian, Broken poly-L-lactic acid interference screw after ligament reconstruction, *Arthroscopy* 18 (2002) E35.
- J.A. Abate, P.D. Fadale, M.J. Hulstyn, W.R. Walsh, Initial fixation strength of polylactic acid interference screws in anterior cruciate ligament reconstruction, *Arthroscopy* 14 (1998) 278–284.
- F.A. Barber, W.D. Dockery, Long-term absorption of poly-L-lactic acid interference screws, *Arthroscopy* 22 (2006) 820–826.
- T. Dvir, B.P. Timko, D.S. Kohane, R. Langer, Nanotechnological strategies for engineering complex tissues, *Nat. Nanotechnol.* 6 (2011) 13–22.
- B. Tian, J. Liu, T. Dvir, L. Jin, J.H. Tsui, Q. Qing, Z. Suo, R. Langer, D.S. Kohane, C.M. Lieber, Macroporous nanowire nanoelectronic scaffolds for synthetic tissues, *Nat. Mater.* 11 (2012) 986–994.
- O. Bostman, H. Pihlajamaki, Clinical biocompatibility of biodegradable orthopaedic implants for internal fixation: a review, *Biomaterials* 21 (2000) 2615–2621.
- I. Grizzi, H. Garreau, S. Li, M. Vert, Hydrolytic degradation of devices based on poly(DL-lactic acid) size-dependence, *Biomaterials* 16 (1995) 305–311.
- C.G. Pitt, M.M. Gratzl, G.L. Kimmel, J. Surles, A. Schindler, Aliphatic polyesters II. The degradation of poly(DL-lactide), poly(epsilon-caprolactone), and their copolymers in vivo, *Biomaterials* 2 (1981) 215–220.
- A. Reed, D. Gilding, Biodegradable polymers for use in surgery poly(glycolic)/poly(lactic acid) homo and copolymers: 2. In vitro degradation, *Polymer* 22 (1980) 494–499.
- G.E. Visscher, R.L. Robison, H.V. Maulding, J.W. Fong, J.E. Pearson, G.J. Argenti, Note – biodegradation of and tissue reaction to poly(DL-lactide) microcapsules, *J. Biomed. Mater. Res.* 20 (1986) 667–676.
- S.W. Zielhuis, J.F. Nijssen, J.H. Seppenwoolde, C.J. Bakker, G.C. Krijger, H.F. Dullens, B.A. Zonnenberg, P.P. van Rijk, W.E. Hennink, A.D. van het Schip, Long-term toxicity of holmium-loaded poly(L-lactic acid) microspheres in rats, *Biomaterials* 28 (2007) 4591–4599.
- R.K. Kulkarni, K.C. Pani, C. Neuman, F. Leonard, Poly(lactic acid) for surgical implants, *Arch. Surg.* 93 (1966) 839–843.
- D.E. Cutright, E.E. Hunsuck, The repair of fractures of the orbital floor using biodegradable polylactic acid, *Oral Surg. Oral Med. Oral Pathol.* 33 (1972) 28–34.
- G. Schwach, M. Vert, In vitro and in vivo degradation of lactic acid-based interference screws used in cruciate ligament reconstruction, *Int. J. Biol. Macromol.* 25 (1999) 283–291.
- A. Tschakaloff, H.W. Losken, R. Vonoepen, W. Michaeli, O. Moritz, M.P. Mooney, A. Losken, Degradation kinetics of biodegradable DL-poly(lactic acid) biodegradable implants depending on the site of implantation, *Int. J. Oral Max. Surg.* 23 (1994) 443–445.
- Z. Xinteng, P. Weisan, Z. Ruhua, Z. Feng, Preparation and evaluation of poly(D, L-lactic acid) (PLA) or D, L-lactide/glycolide copolymer (PLGA) microspheres with estradiol, *Pharmazie* 57 (2002) 695–697.
- M. Jamshidian, E.A. Tehrani, M. Imran, M. Jacquot, S. Desobry, Poly-Lactic Acid: production, applications, nanocomposites, and release studies, *Compr. Rev. Food Sci. Food Safety* 9 (2010) 551–571.
- K. Fukushima, M. Hirata, Y. Kimura, Synthesis and characterization of stereoblock poly(lactic acid)s with nonequivalent D/L sequence ratios, *Macromolecules* 40 (2007) 3049–3055.
- H. Lehermeier, J. Dorgan, J. Way, Gas permeation properties of poly(lactic acid), *J. Membr. Sci.* 190 (2001) 243–251.
- D.J. Mooney, D.F. Baldwin, N.P. Suh, J.P. Vacanti, R. Langer, Novel approach to fabricate porous sponges of poly(D, L-lactic-co-glycolic acid) without the use of organic solvents, *Biomaterials* 17 (1996) 1417–1422.
- A.G. Mikos, A.J. Thorsen, L.A. Czerwonka, Y. Bao, R. Langer, D.N. Winslow, J.P. Vacanti, Preparation and characterization of poly(L-lactic acid) foams, *Polymer* 35 (1994) 1068–1077.
- A. Gopferich, Mechanisms of polymer degradation and erosion, *Biomaterials* 17 (1996) 103–114.
- L. Xu, K. Crawford, C.B. Gorman, Effects of temperature and pH on the degradation of poly(lactic acid) brushes, *Macromolecules* 44 (2011) 4777–4782.
- X. Zhang, Y. Lin, R.J. Gillies, Tumor pH and its measurement, *J. Nucl. Med.* 51 (2010) 1167–1170.
- E.S. Lee, Z. Gao, Y.H. Bae, Recent progress in tumor pH targeting nanotechnology, *J. Control. Release* 132 (2008) 164–170.
- R. Kulkarni, E. Moore, A. Hegyeli, A.S. Fred Leonard, Biodegradable poly(lactic acid) polymers, *J. Biomed. Mater. Res.* 5 (1971) 169–181.
- L.R. Beck, D.R. Cowsar, D.H. Lewis, J.W. Gibson, C.E. Flowers Jr., New long-acting injectable microcapsule contraceptive system, *Am. J. Obstet. Gynecol.* 135 (1979) 419–426.
- M.S. Shive, J.M. Anderson, Biodegradation and biocompatibility of PLA and PLGA microspheres, *Adv. Drug Deliv. Rev.* 28 (1997) 5–24.
- R.K. Kulkarni, E.G. Moore, A.F. Hegyeli, F. Leonard, Biodegradable poly(lactic acid) polymers, *J. Biomed. Mater. Res.* 5 (1971) 169–181.
- R. Langer, H. Brem, K. Faltermann, M. Klein, J. Folkman, Isolations of a cartilage factor that inhibits tumor neovascularization, *Science* 193 (1976) 70–72.

- [55] H. Brem, S. Piantadosi, P.C. Burger, M. Walker, R. Selker, N.A. Vick, K. Black, M. Sisti, S. Brem, G. Mohr, et al., Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group, *Lancet* 345 (1995) 1008–1012.
- [56] J. Folkman, R. Langer, R.J. Linhardt, C. Haudenschild, S. Taylor, Angiogenesis inhibition and tumor regression caused by heparin or a heparin fragment in the presence of cortisone, *Science* 221 (1983) 719–725.
- [57] J. Kost, R. Langer, Responsive polymeric delivery systems, *Adv. Drug Deliv. Rev.* 46 (2001) 125–148.
- [58] D.S. Kohane, J.Y. Tse, Y. Yeo, R. Padera, M. Shubina, R. Langer, Biodegradable polymeric microspheres and nanospheres for drug delivery in the peritoneum, *J. Biomed. Mater. Res. Part A* 77 (2006) 351–361.
- [59] D. Williams, Enzymic hydrolysis of polylactic acid, *Eng. Med.* 10 (1981) 5–7.
- [60] K. Nakamura, T. Tomita, N. Abe, Y. Kamio, Purification and characterization of an extracellular poly(L-lactic acid) depolymerase from a soil isolate, *Amycolatopsis* sp. strain K104–1, *Appl. Environ. Microbiol.* 67 (2001) 345–353.
- [61] H. Cai, V. Dave, R.A. Gross, S.P. McCarthy, Effects of physical aging, crystallinity, and orientation on the enzymatic degradation of poly(lactic acid), *J. Polymer Sci.* 34 (1996) 2701–2708.
- [62] A. Schroeder, K. Turjeman, J.E. Schroeder, M. Leibergall, Y. Barenholz, Using liposomes to target infection and inflammation induced by foreign body injuries or medical implants, *Expert Opin. Drug Deliv.* 7 (2010) 1175–1189.
- [63] M. Colilla, M. Manzano, M. Vallet-Regi, Recent advances in ceramic implants as drug delivery systems for biomedical applications, *Int. J. Nanomed.* 3 (2008) 403–414.
- [64] J.M. Schakenraad, M.J. Hardonk, J. Feijen, I. Molenaar, P. Nieuwenhuis, Enzymatic activity toward poly(L-lactic acid) implants, *J. Biomed. Mater. Res.* 24 (1990) 529–545.
- [65] R. Goldbart, T. Traitel, S.A. Lapidot, J. Kost, Enzymatically controlled responsive drug delivery systems, *Polymers Adv. Technol.* 13 (2002) 1006–1018.
- [66] S. Stener, L. Ejerhed, N. Sernert, G. Laxdal, L. Rostgard-Christensen, J. Kartus, A. Long-term, Prospective, randomized study comparing biodegradable and metal interference screws in anterior cruciate ligament reconstruction surgery: radiographic results and clinical outcome, *Am. J. Sports Med.* 38 (2010) 1598–1605.
- [67] A. Swed, T. Cordonnier, A. Denarnaud, C. Boyer, J. Guicheux, P. Weiss, F. Boury, Sustained release of TGF- β 1 from biodegradable microparticles prepared by a new green process in CO₂ medium, *Int. J. Pharm.* 493 (2015) 357–365.
- [68] Y. Matsumura, K. Kataoka, Preclinical and clinical studies of anticancer agent-incorporating polymer micelles, *Cancer Sci.* 100 (2009) 572–579.
- [69] U. Kedar, P. Phutane, S. Shidhaye, V. Kadam, Advances in polymeric micelles for drug delivery and tumor targeting, *Nanomed. Nanotechnol.* 6 (2010) 714–729.
- [70] Y. Liu, J. Li, F. Liu, L. Feng, D. Yu, N. Zhang, Theranostic polymeric micelles for the diagnosis and treatment of hepatocellular carcinoma, *J. Biomed. Nanotechnol.* 11 (2015) 613–622.
- [71] C. Yang, H. Vu-Quang, D.M.U. Husum, S.J. Tingskov, M.S. Vinding, T. Nielsen, P. Song, N.C. Nielsen, R. Norregaard, J. Kjems, Theranostic poly(lactic-co-glycolic acid) nanoparticle for magnetic resonance/infrared fluorescence bimodal imaging and efficient siRNA delivery to macrophages and its evaluation in a kidney injury model, *Nanomedicine* 13 (2017) 2451–2462.
- [72] C. Perez, A. Sanchez, D. Putnam, D. Ting, R. Langer, M.J. Alonso, Poly(lactic acid)-poly(ethylene glycol) nanoparticles as new carriers for the delivery of plasmid DNA, *J. Control Release* 75 (2001) 211–224.
- [73] M.S. Muthu, D.T. Leong, L. Mei, S.S. Feng, Nanotheranostics – application and further development of nanomedicine strategies for advanced theranostics, *Theranostics* 4 (2014) 660–677.
- [74] M.P. Stewart, A. Lorenz, J. Dahlman, G. Sahay, Challenges in carrier-mediated intracellular delivery: moving beyond endosomal barriers, *Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol.* 8 (2016) 465–478.
- [75] C. Fetsch, J. Gaitzsch, L. Messenger, G. Battaglia, R. Luxenhofer, Self-assembly of amphiphilic block copolypeptides – micelles, Worms and Polymersomes, *Sci. Rep.* 6 (2016) 33491.
- [76] B.P. Timko, T. Dvir, D.S. Kohane, Remotely triggerable drug delivery systems, *Adv. Mater.* 22 (2010) 4925–4943.
- [77] D.T. Martin, J.M. Steinbach, J. Liu, S. Shimizu, H.Z. Kaimakliotis, M.A. Wheeler, A.B. Hittelman, W. Mark Saltzman, R.M. Weiss, Surface-modified nanoparticles enhance transurothelial penetration and delivery of survivin siRNA in treating bladder cancer, *Mol. Cancer Ther.* 13 (2014) 71–81.
- [78] S. Konan, F.S. Haddad, A clinical review of bioabsorbable interference screws and their adverse effects in anterior cruciate ligament reconstruction surgery, *Knee* 16 (2009) 6–13.
- [79] O.M. Böstman, H.K. Pihlajamäki, Adverse tissue reactions to bioabsorbable fixation devices, *Clin. Orthopaed. Related Res.* 371 (2000) 216–227.
- [80] J.M. Anderson, A. Rodriguez, D.T. Chang, Foreign body reaction to biomaterials, *Semin. Immunol.* 20 (2008) 86–100.
- [81] G. Gonzalez-Lomas, R.T. Cassilly, F. Remotti, W.N. Levine, Is the etiology of pre-tibial cyst formation after absorbable interference screw use related to a foreign body reaction? *Clin. Orthopaed. Related Res.* 469 (2011) 1082–1088.
- [82] T.K. Kim, T.W. Jeong, D.H. Lee, Foreign body reaction after PLC reconstruction caused by a broken PLLA screw, *Orthopedics* 37 (2014) E1129–E1132.
- [83] D.S. Mastrokalos, H.H. Paessler, Allergic reaction to biodegradable interference poly-L-lactic acid screws after anterior cruciate ligament reconstruction with bone-patellar tendon-bone graft, *Arthroscopy* 24 (2008) 732–733.
- [84] J.J. Oppenheimer, H.S. Nelson, S.A. Bock, F. Christensen, D.Y. Leung, Treatment of peanut allergy with rush immunotherapy, *J. Allergy Clin. Immunol.* 90 (1992) 256–262.
- [85] G.J. Moyle, S. Brown, L. Lysakova, S.E. Barton, Long-term safety and efficacy of poly-L-lactic acid in the treatment of HIV-related facial lipoatrophy, *HIV Med.* 7 (2006) 181–185.
- [86] S. Shahrabi-Farahani, M.A. Lerman, V. Noonan, S. Kabani, S.B. Woo, Granulomatous foreign body reaction to dermal cosmetic fillers with intraoral migration, *Oral Surg. Oral Med. Oral Pathol. Oral Radiol.* 117 (2014) 105–110.
- [87] K. Rezwan, Q.Z. Chen, J.J. Blaker, A.R. Boccaccini, Biodegradable and bioactive porous polymer/inorganic composite scaffolds for bone tissue engineering, *Biomaterials* 27 (2006) 3413–3431.
- [88] H.N. Chia, B.M. Wu, Recent advances in 3D printing of biomaterials, *J. Biol. Eng.* 9 (2015) 4.
- [89] F. Rengier, A. Mehndiratta, H. von Tengg-Kobligk, C.M. Zechmann, R. Unterhinninghofen, H.U. Kauczor, F.L. Giesel, 3D printing based on imaging data: review of medical applications, *Int. J. Comput. Assisted Radiol. Surg.* 5 (2010) 335–341.
- [90] T. Serra, M.A. Mateos-Timoneda, J.A. Planell, M. Navarro, 3D printed PLA-based scaffolds: a versatile tool in regenerative medicine, *Organogenesis* 9 (2013) 239–244.
- [91] T. Serra, M. Ortiz-Hernandez, E. Engel, J.A. Planell, M. Navarro, Relevance of PEG in PLA-based blends for tissue engineering 3D-printed scaffolds, *Mater. Sci. Eng. C* 38 (2014) 55–62.
- [92] M. Stoppato, E. Carletti, V. Sidarovich, A. Quattrone, R.E. Unger, C.J. Kirkpatrick, C. Migliaresi, A. Motta, Influence of scaffold pore size on collagen I development: a new in vitro evaluation perspective, *J. Bioact. Compat. Pol.* 28 (2013) 16–32.
- [93] C.T. Kao, C.C. Lin, Y.W. Chen, C.H. Yeh, H.Y. Fang, M.Y. Shie, Poly(dopamine) coating of 3D printed poly(lactic acid) scaffolds for bone tissue engineering, *Mater. Sci. Eng. C* 56 (2015) 165–173.
- [94] J. Yang, G. Shi, J. Bei, S. Wang, Y. Cao, Q. Shang, G. Yang, W. Wang, Fabrication and surface modification of macroporous poly(L-lactic acid) and poly(L-lactic-co-glycolic acid) (70/30) cell scaffolds for human skin fibroblast cell culture, *J. Biomed. Mater. Res.* 62 (2002) 438–446.
- [95] S.S. Liao, F.Z. Cui, W. Zhang, Q.L. Feng, Hierarchically biomimetic bone scaffold materials: nano-HA/collagen/PLA composite, *J. Biomed. Mater. Res. Part B* 69 (2004) 158–165.
- [96] T. Serra, J.A. Planell, M. Navarro, High-resolution PLA-based composite scaffolds via 3-D printing technology, *Acta Biomater.* 9 (2013) 5521–5530.
- [97] L. Cao, P.G. Duan, H.R. Wang, X.L. Li, F.L. Yuan, Z.Y. Fan, S.M. Li, J. Dong, Degradation and osteogenic potential of a novel poly(lactic acid)/nano-sized beta-tricalcium phosphate scaffold, *Int. J. Nanomed.* 7 (2012) 5881–5888.
- [98] H. Schliephake, H.A. Weich, C. Dullin, R. Gruber, S. Frahse, Mandibular bone repair by implantation of rhBMP-2 in a slow release carrier of polylactic acid—an experimental study in rats, *Biomaterials* 29 (2008) 103–110.